Phathom Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€97.84M - Cost of goods sold
€12.81M - Gross profit
€85.03M - SG&A expenses
€285.34M - R&D expenses
€30.49M - EBITDA
-€222.69M - D&A
€477.05K - EBIT
-€230.80M - Interest expenses
€62.35M - EBT
-€202.35M - Tax expenses
€0.00 - Net income
-€202.35M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€25.73M - Changes in working capital
-€1.19M - Operating cash flow
-€235.68M - Capex
-€69.50K - Other investing cash flow
-€210.21K - Net investing cash flow
-€140.71K - Total cash dividends paid
€0.00 - Issuance of common stock
-€18.02K - Debt repayment
€21.24M - Other financing cash flow
€1.42M - Net financing cash flow
€127.14M - Foreign exchange effects
€0.00 - Net change in cash
-€106.23M - Cash at end of period
€130.79M - Free cash flow
-€235.75M
Balance sheet
- Cash and cash equivalents
€128.33M - Cash and short-term investments
€128.33M - Total receivables
€43.98M - Inventory
€2.94M - Other current assets
€12.54M - Total current assets
€187.79M - Property, plant & equipment
€1.81M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€2.46M - Other non-current assets
€22.62M - Total non-current assets
€26.89M - Total assets
€214.69M - Accounts payable
€3.44M - Short-term debt
€18.67M - Other current liabilities
€56.67M - Total current liabilities
€78.78M - Long-term debt
€474.24M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€9.87M - Total non-current liabilities
€484.11M - Total liabilities
€562.89M - Common stock
€5.15K - Retained earnings
-€1.23B - Other equity
€0.00 - Total equity
-€348.21M - Total liabilities and shareholders' equity
€214.69M
Company information
- Market capitalization
€580.00M - Employees
427 - Enterprise Value
€622.37M
Company ratios
- Gross margin
-
86.9% Much better than peer group: -926.8% - EBITDA margin
-
-227.6% Much better than peer group: -39,364.2% - EBIT margin
-
-235.9% Much better than peer group: -39,792.4% - EBT margin
-
-206.8% Much better than peer group: -38,966.8% - Net margin
-
-206.8% Much better than peer group: -38,784.9% - ROE
-
58.1% Much better than peer group: -12,701.6% - ROA
-
-94.3% Better than peer group: -111.5% - Asset turnover
-
45.6% Much better than peer group: -2.8% - FCF margin
-
-240.8% Much better than peer group: -34,520.3% - FCF yield
-40.6% - Efficiency ratio
327.6% - Net sales per employee
-
€229.14K - Net income per employee
-
-€473.89K